Pharmaceutical Drug Delivery Market

Pharmaceutical Drug Delivery Market by Route (Oral (Tablet), Pulmonary (Nebulizer), Injectable, Ocular (Liquid), Topical (Solid), Implantable (Active), Transmucosal), Application (Cancer, Diabetes), Patient Care Setting (Hospital)- COVID-19 Impact - Forecast to 2025

Report Code: MD 3871 Jul, 2020, by marketsandmarkets.com

[459 Pages Report] The pharmaceutical drug delivery technology market is projected to reach USD 2,015.3 billion by 2025 from USD 1,430.5 billion in 2020, at a CAGR of 7.1% during the forecast period. Growth in this market is mainly driven by the rising prevalence of chronic diseases, growth in the biologics market, and technological advancements and new product launches. Due to the outbreak of corona virus globally, there is a sudden rise in the demand for pharmaceutical drugs largely in infectious application.

Pharmaceutical Drug Delivery Market

COVID-19 Impact on the Pharmaceutical Drug Delivery Technology Market

Coronavirus has spread across 215 countries and territories and affected more than 4.4 million people, with close to 300 thousand deaths. Due to the COVID-19 outbreak, we are estimating that the share of infectious diseases segment has increased and is anticipated that this segment will grow significantly during the forecast period. COVID-19 has given momentum to drug delivery market and it will show significant growth rate during 2020-2021

The outbreak of COVID-19 has been increasing at an exponential level in many countries. This has led to the need to improve patient care and provide added nutritional/immunity support (including vitamins and other curing drugs) to patients affected by the virus. This has led to an increased adoption of drugs, such as vit C, multivitamin, antiviral and so on, which in turn is expected to support market growth to a certain extent

Coronavirus has spread across 215 countries and territories and affected more than 4.4 million people, with close to 300 thousand deaths. Due to the outbreak of COVID-19 globally, medical practices of all sizes are under immense pressure, and healthcare providers need to rely on teleradiology solutions to read diagnostic reports and treat patients. Teleradiology solutions also help to improve the efficiency of diagnostic imaging by optimizing and simplifying radiology with correct reads and reduced manual errors. As the battle against COVID-19 continues, there is a growing need to make teleradiology solutions more common.

There are large number of drugs and vaccines in various clinical trial phases which are expected to be launched in coming months/years under emergency usage authorization guidelines for treating COVID-19. As of May 2020, two vaccines are in Phase I clinical evaluation and 11 in pre-clinical stage. About 95 clinical studies are on-going for COVID-19 as potential drug therapies. Such strong pipeline is anticipated to drive the growth of this market.

Pharmaceutical Drug Delivery Technology Market Dynamics

Drivers:  Growth in biologics market

According to the American Journal of Managed Health Care, biologics form the fastest-growing segment of the pharmaceutical market. An article published by Congressional Research Service 2017, stated that in the US, in 2016, spending on biologics increased by 13% (as compared to 2015) to reach USD 105.5 billion. According to an article published by The Economist, in the US, more than 900 biologics are under development for the treatment of more than 100 diseases. It is estimated that biologics contributed approximately 22% of the sales of large pharmaceuticals companies in 2013, which is expected to reach 32% by 2023. As biologics are mainly administered by the injectable route, the significant growth in the biologics market is expected to drive the injectable drug delivery market in the coming years. According to Pharmaceutical Research and Manufacturers of America (formerly known as the Pharmaceutical Manufacturers Association), as of June 2020, there are 17 biosimilars in the US market against 7 reference biologics

Restrains: Risk of needlestick injuries

Needlestick injuries are one of the major risks in injectable drug delivery. According to PharmaJet, in the US, around 600,000 to 800,000 needlestick injuries are reported every year. The Occupational Safety and Health Administration (OSHA) estimates that around 5.6 million workers in the US are at the risk of exposure to blood-borne pathogens due to needlestick injuries. Furthermore, the CDC estimates that an average of 385,000 needlestick injuries occur annually in US hospital settings. Similarly, in Europe, more than 1 million needlestick injuries are reported each year (Source: Becton, Dickinson and Company). In Sweden, one needlestick injury is reported per 200 employees each year, while in Germany, the estimated number of needlestick injuries in hospitals is around 500,000 per year. Further, according to the WHO, it was found that 37.6% of Hepatitis B, 39% of Hepatitis C, and 4.4% of HIV/AIDS cases in healthcare workers around the world are caused due to needlestick injuries

Opportunities: Rising demand for biosimilars

Biosimilars are more acceptable for the treatment of chronic diseases that are of a non-life-threatening nature. Moreover, biosimilars can drive the overall therapeutics market by allowing patients to access drugs at cheaper rates. The lower cost of manufacturing due to the use of modern manufacturing technologies for the development of biosimilars is a major factor that is expected to drive the growth of this market in the coming years. Also, an increasing number of companies are conducting clinical trials on biosimilars. For instance, Biocon is involved in the clinical trials of various drugs such as Insulin Glargine, Trastuzumab, Bevacizumab, Pegfilgrastim, and Adalimumab. Also, Amgen is conducting clinical trials for various biosimilars, such as rituximab, infliximab, centuximab, eculizumab, and trastuzumab. Some FDA-approved biosimilars include Zarxio (Sandoz), AMJEVITA (Amgen), and Erelzi (Sandoz).

Challenges: Pricing pressure

Governments in both developed and developing countries are encouraging cost-saving measures such as cutting drug reimbursement prices or promoting the greater use of generics. Drug manufacturers across the globe are facing significant cost reduction pressures from governments, insurers, and patients. This downward pricing pressure is resulting in the greater uptake of drugs in emerging markets where the demand for low-cost therapeutics is high. However, this is affecting the profitability of several pharmaceutical companies. This trend is expected to continue in the coming years owing to the continuous pressure for reducing pharmaceutical prices by insurers, pharmacy benefit managers (PBMs), and public and private payers due to concerns about covering more new medicines to treat prevalent conditions such as high cholesterol and diabetes, thereby challenging slightly the growth of this market.

The topical drug delivery market is expected to grow at the highest CAGR during the forecast period.

Based on route of administration, the pharmaceutical drug delivery market is segmented into oral, pulmonary, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. The topical drug delivery market is expected to grow at the highest CAGR during the forecast period. Growth in this segment can be attributed to the wide range of advantages associated with this route of administration, including convenience and ease of use, right dosage to the right place, painless and noninvasive delivery, superior spreadability, and enhanced patient compliance.

Growing demand for biosimilars to drive the market for conventional injection devices

Based on type, the injectable drug delivery technology market is segmented into conventional injection devices, self-injection devices, and other devices. The conventional injection devices segment accounted for the largest market share in 2019. The large share of this segment is due to the increasing prevalence of chronic diseases (particularly cancer and diabetes) and CVD, growing demand for biosimilar products, and low cost of devices and manufacturing.

Hospitals were estimated to be the largest facility of use of pharmaceutical drug delivery in 2019

On the basis of facility of use, the pharmaceutical drug delivery market is segmented into hospitals, ambulatory surgical centers (ASCs)/clinics, diagnostic centers, home care settings, and other facilities of use. In 2019, the hospitals segment accounted for the largest share of the pharmaceutical drug delivery market. This can be attributed to the significant number of inpatient and outpatient visits to hospitals and the requirement of large volumes of drugs and their respective delivery devices to cater to the demand of the large patient pool.

In 2019, North America accounted for the largest share of the market

Geographically, North America accounted for the largest share of 39.3% of the market in 2019, followed by Europe. The large share of the North American market is due to factors such as growth in biologics in the pharmaceuticals market; the rising prevalence of chronic diseases such as cancer, respiratory allergies, and diabetes; increasing patient compliance to innovative drug delivery technologies; and the presence of a large number of prominent players in this region.

Pharmaceutical Drug Delivery Market by Region

Key Market Players

The global pharmaceutical drug delivery market is highly fragmented owing to the presence of several large and small players. Johnson & Johnson, Inc. (US), F. Hoffman-La Roche (Switzerland), Merck & Co., Inc. (US), Bayer AG (Germany), Pfizer, Inc. (US), Novartis AG (Switzerland), 3M Company (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc, (UK), Sanofi (France), and Antares Pharma, Inc. (US) are some of the leading players operating in the market.

Johnson & Johnson, Inc is one of the prominent players in the pharmaceutical drug delivery market. The company offers a robust product portfolio and has a strong geographical presence in this market. The company has 125 manufacturing facilities all across the globe. J&J primarily focuses on products related to human health and well-being. Innovation is an integral part of the company. The firm is committed to improving human therapeutic medicines through continuous investment in R&D.

Novartis AG is another leading player in the pharmaceutical drug delivery market. The company’s strong brand recognition and extensive product portfolio in this market are its key strengths. To maintain its leading position in the market, the company adopts organic as well as inorganic growth strategies such as acquisitions and expansions.

Scope of the report

Report Metric

Details

Market size available for years

2016–2025

Base year considered

2019

Forecast period

2020–2025

Forecast units

Value (USD)

Segments covered

Route of administration, applications, facility of use, and region

Geographies covered

North America, Asia Pacific, Europe, and the Rest of the World

Companies covered

Johnson & Johnson, Inc. (US), F. Hoffman-La Roche (Switzerland), Merck & Co., Inc. (US), Bayer AG (Germany), Pfizer, Inc. (US), Novartis AG (Switzerland), 3M Company (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc, (UK), Sanofi (France), Antares Pharma, Inc. (US), AbbVie (US), Amgen (US), Boehringer Ingelheim (Germany), AstraZeneca (UK), Eli Lilly and Company (US), Gilead Sciences, Inc. (US), Teva Pharmaceuticals (Israel), Bristol-Myers Squibb (US) and Genmab A/S (Denmark)

This report categorizes the pharmaceutical drug delivery market into the following segments and subsegments:

Pharmaceutical Drug Delivery Market, by Route of Administration

  • Oral Drug Delivery
  • Pulmonary Drug Delivery
  • Injectable Drug Delivery
  • Ocular Drug Delivery
  • Nasal Drug Delivery
  • Topical Drug Delivery
  • Implantable Drug Delivery
  • Transmucosal Drug Delivery

Pharmaceutical Drug Delivery Market, by Application

  • Infectious Diseases
  • Cancer
  • Cardiovascular Diseases
  • Diabetes
  • Respiratory Diseases
  • Central Nervous System Disorders
  • Autoimmune Diseases

Pharmaceutical Drug Delivery Market, by Facility of Use

  • Hospitals
  • Home Care Settings
  • ASC/Clinics
  • Diagnostic Centers

Pharmaceutical Drug Delivery Market, by Region

  • North America
  • Europe
  • Asia Pacific
  • RoW

Recent Developments

  • In 2020, Johnson & Johnson, Inc collaborated with Biomedical Advanced Research and Development Authority (BARDA), to expedite development and strengthen access through production of coronavirus vaccine.
  • In 2020, Johnson & Johnson, Inc collaborated with MeiraGTx Holdings Plc (US) to develop, manufacture and commercialize its clinical stage inherited retinal disease drug portfolio
  • In 2019, Novartis signed an agreement with Shionogi (Japan) to commercialize new treatment, Rizmoic (Naldemedine) for Opiod-induced constipation in key European countries of Germany, UK and Netherlands, with rights of first refusal for some other European markets.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 60)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION AND SCOPE
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
                 FIGURE 1 DRUG DELIVERY TECHNOLOGY MARKET SEGMENTATION
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 64)
    2.1 RESEARCH DATA
        FIGURE 2 DRUG DELIVERY TECHNOLOGY MARKET: RESEARCH METHODOLOGY
        FIGURE 3 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
    2.2 MARKET SIZING & VALIDATION APPROACH
    2.3 MARKET SIZE ESTIMATION
        FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
        FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
           2.3.1 MARKET DATA VALIDATION AND TRIANGULATION
                 FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 74)
  FIGURE 8 DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020 VS. 2025 (USD BILLION)
  FIGURE 9 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2020 VS. 2025 (USD BILLION)
  FIGURE 10 DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020 VS. 2025 (USD BILLION)
  FIGURE 11 DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2020 VS. 2025 (USD BILLION)
  FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE DRUG DELIVERY TECHNOLOGY MARKET

4 PREMIUM INSIGHTS (Page No. - 78)
    4.1 DRUG DELIVERY TECHNOLOGY MARKET OVERVIEW
        FIGURE 13 RISING PREVALENCE OF CHRONIC DISEASES IS DRIVING THE GROWTH OF THE DRUG DELIVERY TECHNOLOGY MARKET
    4.2 DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020 VS. 2025 (USD BILLION)
        FIGURE 14 TOPICAL DRUG DELIVERY SEGMENT TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
    4.3 DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020–2025 (USD BILLION)
        FIGURE 15 HOME CARE SETTINGS ARE THE FASTEST-GROWING END USERS OF DRUG DELIVERY TECHNOLOGIES
    4.4 DRUG DELIVERY TECHNOLOGY MARKET SHARE, BY APPLICATION AND REGION, 2019
        FIGURE 16 INFECTIOUS DISEASES SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2019
    4.5 DRUG DELIVERY TECHNOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
        FIGURE 17 CHINA IS EXPECTED TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 82)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
        FIGURE 18 DRUG DELIVERY TECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    5.3 DRIVERS
           5.3.1 RISING PREVALENCE OF CHRONIC DISEASES
           5.3.2 GROWTH IN THE BIOLOGICS MARKET
                 TABLE 1 INDICATIVE LIST OF BIOLOGICS APPROVED BY THE FDA (2020)
           5.3.3 TECHNOLOGICAL ADVANCEMENTS AND NEW PRODUCT LAUNCHES
    5.4 RESTRAINTS
           5.4.1 RISK OF NEEDLESTICK INJURIES
    5.5 OPPORTUNITIES
           5.5.1 SELF-ADMINISTRATION AND HOME CARE
           5.5.2 RISING DEMAND FOR BIOSIMILARS
    5.6 CHALLENGES
           5.6.1 PRICING PRESSURE
    5.7 COVID-19 IMPACT ON THE DRUG DELIVERY TECHNOLOGY MARKET
        FIGURE 19 IMPACT OF COVID-19 ON THE DRUG DELIVERY TECHNOLOGY MARKET

6 DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 89)
    6.1 INTRODUCTION
        FIGURE 20 TOPICAL DRUG DELIVERY SEGMENT TO REGISTER THE HIGHEST GROWTH IN THE DRUG DELIVERY TECHNOLOGY MARKET FROM 2020 TO 2025
        TABLE 2 DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2019 (USD BILLION)
        TABLE 3 DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD BILLION)
    6.2 ORAL DRUG DELIVERY
        TABLE 4 ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016–2019 (USD BILLION)
        TABLE 5 ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2020–2025 (USD BILLION)
        TABLE 6 ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016–2019 (USD BILLION)
        TABLE 7 ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2020–2025 (USD BILLION)
           6.2.1 SOLID ORAL DRUGS
                 TABLE 8 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2016–2019 (USD BILLION
                 TABLE 9 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
                 TABLE 10 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY REGION, 2016–2019 (USD BILLION)
                 TABLE 11 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY REGION, 2020–2025 (USD BILLION)
                    6.2.1.1 Tablets
                               6.2.1.1.1 Development of mini-tablets is a key trend in this market segment
                                         TABLE 12TABLETS MARKET, BY REGION, 2016–2019 (USD BILLION)
                                         TABLE 13 TABLETS MARKET, BY REGION, 2020–2025 (USD BILLION)
                    6.2.1.2 Capsules
                               6.2.1.2.1 Easy absorption of drugs and decreased irritation in the GI tract are driving the use of capsules
                                         TABLE 14 CAPSULES MARKET, BY REGION, 2016–2019 (USD BILLION)
                                         TABLE 15 CAPSULES MARKET, BY REGION, 2020–2025 (USD BILLION)
                    6.2.1.3 Powders
                               6.2.1.3.1 Powders are taken by patients who are unable to swallow oral dosage forms
                                         TABLE 16 POWDERS MARKET, BY REGION, 2016–2019 (USD BILLION)
                                         TABLE 17 POWDERS MARKET, BY REGION, 2020–2025 (USD BILLION)
                    6.2.1.4 Pills
                               6.2.1.4.1 Rising incidence of target ailments will propel the growth of the pills market
                                         TABLE 18 PILLS MARKET, BY REGION, 2016–2019 (USD BILLION)
                                         TABLE 19 PILLS MARKET, BY REGION, 2020–2025 (USD BILLION)
           6.2.2 LIQUID ORAL DRUGS
                 TABLE 20 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2016–2019 (USD BILLION)
                 TABLE 21 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
                 TABLE 22 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY REGION, 2016–2019 (USD BILLION)
                 TABLE 23 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY REGION, 2020–2025 (USD BILLION)
                    6.2.2.1 Syrups
                               6.2.2.1.1 Liquid syrups can be easily administered to patients with swallowing difficulties
                                         TABLE 24 ORAL SYRUPS MARKET, BY REGION, 2016–2019 (USD BILLION)
                                         TABLE 25 ORAL SYRUPS MARKET, BY REGION, 2020–2025 (USD BILLION)
                    6.2.2.2 Solutions
                               6.2.2.2.1 Solutions are generally preferred by geriatric and pediatric patients
                                         TABLE 26 ORAL SOLUTIONS MARKET, BY REGION, 2016–2019 (USD BILLION)
                                         TABLE 27 ORAL SOLUTIONS MARKET, BY REGION, 2020–2025 (USD BILLION)
           6.2.3 SEMI-SOLID ORAL DRUGS
                 TABLE 28 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2016–2019 (USD BILLION)
                 TABLE 29 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
                 TABLE 30 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY REGION, 2016–2019 (USD BILLION)
                 TABLE 31 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY REGION, 2020–2025 (USD BILLION)
                    6.2.3.1 Gels
                               6.2.3.1.1 Gels are used for controlled drug release
                                         TABLE 32 ORAL GELS MARKET, BY REGION, 2016–2019 (USD BILLION)
                                         TABLE 33 ORAL GELS MARKET, BY REGION, 2020–2025 (USD BILLION)
                    6.2.3.2 Emulsions
                               6.2.3.2.1 Microemulsions offer protection against oxidation and enzymatic hydrolysis
                                         TABLE 34 ORAL EMULSIONS MARKET, BY REGION, 2016–2019 (USD BILLION)
                                         TABLE 35 ORAL EMULSIONS MARKET, BY REGION, 2020–2025 (USD BILLION)
                    6.2.3.3 Elixirs
                               6.2.3.3.1 Elixirs are hydraulic in nature and contain sweet and flavored substances
                                         TABLE 36 ELIXIRS MARKET, BY REGION, 2016–2019 (USD MILLION)
                                         TABLE 37 ELIXIRS MARKET, BY REGION, 2020–2025 (USD MILLION)
    6.3 INJECTABLE DRUG DELIVERY
        TABLE 38 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016–2019 (USD BILLION)
        TABLE 39 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2020–2025 (USD BILLION)
        TABLE 40 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 41 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD BILLION)
           6.3.1 CONVENTIONAL INJECTION DEVICES
                 TABLE 42 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY REGION, 2016–2019 (USD BILLION)
                 TABLE 43 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY REGION, 2020–2025 (USD BILLION)
                    6.3.1.1 By material
                            TABLE 44 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2016–2019 (USD BILLION)
                            TABLE 45 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2020–2025 (USD BILLION)
                               6.3.1.1.1 Glass
                                             6.3.1.1.1.1 Glass syringes are considered to be one of the most durable and safe materials to store biologic drugs
                                                         TABLE 46 GLASS SYRINGES MARKET, BY REGION, 2016–2019 (USD BILLION)
                                                         TABLE 47 GLASS SYRINGES MARKET, BY REGION, 2020–2025 (USD BILLION)
                               6.3.1.1.2 Plastic
                                             6.3.1.1.2.1 Plastic syringes are reasonably priced as compared to their glass counterparts
                                                         TABLE 48 PLASTIC SYRINGES MARKET, BY REGION, 2016–2019 (USD BILLION)
                                                         TABLE 49 PLASTIC SYRINGES MARKET, BY REGION, 2020–2025 (USD BILLION)
                    6.3.1.2 By product
                            TABLE 50 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2016–2019 (USD BILLION)
                            TABLE 51 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2020–2025 (USD BILLION)
                               6.3.1.2.1 Fillable syringes
                                             6.3.1.2.1.1 Ease of use and variable dosing formulations of fillable syringes are the major factors driving market growth
                                                         TABLE 52 FILLABLE SYRINGES MARKET, BY REGION, 2016–2019 (USD BILLION)
                                                         TABLE 53 FILLABLE SYRINGES MARKET, BY REGION, 2020–2025 (USD BILLION)
                               6.3.1.2.2 Prefilled syringes
                                             6.3.1.2.2.1 Prefilled syringes offer improved dose accuracy and increased patient convenience and safety
                                                         TABLE 54 PREFILLED SYRINGES MARKET, BY REGION, 2016–2019 (USD BILLION)
                                                         TABLE 55 PREFILLED SYRINGES MARKET, BY REGION, 2020–2025 (USD BILLION)
                    6.3.1.3 By usability
                            TABLE 56 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2016–2019 (USD BILLION)
                            TABLE 57 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2020–2025 (USD BILLION)
                               6.3.1.3.1 Reusable syringes
                                             6.3.1.3.1.1 Reusable syringes are easy to dismantle and clean
                                                         TABLE 58 REUSABLE SYRINGES MARKET, BY REGION, 2016–2019 (USD BILLION)
                                                         TABLE 59 REUSABLE SYRINGES MARKET, BY REGION, 2020–2025 (USD BILLION)
                               6.3.1.3.2 Disposable syringes
                                             6.3.1.3.2.1 Disposable syringes are widely used in medical practices due to their low cost and convenience
                                                         TABLE 60 DISPOSABLE SYRINGES MARKET, BY REGION, 2016–2019 (USD BILLION)
                                                         TABLE 61 DISPOSABLE SYRINGES MARKET, BY REGION, 2020–2025 (USD BILLION)
           6.3.2 SELF-INJECTION DEVICES
                 TABLE 62 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2016–2019 (USD BILLION)
                 TABLE 63 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2020–2025 (USD BILLION)
                 TABLE 64 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY REGION, 2016–2019 (USD BILLION)
                 TABLE 65 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY REGION, 2020–2025 (USD BILLION)
                    6.3.2.1 Needle-free injectors
                               6.3.2.1.1 Needle-free injectors enable fast drug delivery and show better reproducibility as compared to invasive drug delivery systems
                                         TABLE 66 NEEDLE-FREE INJECTORS MARKET, BY REGION, 2016–2019 (USD BILLION)
                                         TABLE 67 NEEDLE-FREE INJECTORS MARKET, BY REGION, 2020–2025 (USD BILLION)
                    6.3.2.2 Autoinjectors
                               6.3.2.2.1 Autoinjectors provide improved patient satisfaction as compared to manual injections
                                         TABLE 68 AUTOINJECTORS MARKET, BY REGION, 2016–2019 (USD BILLION)
                                         TABLE 69 AUTOINJECTORS MARKET, BY REGION, 2020–2025 (USD BILLION)
                    6.3.2.3 Pen injectors
                               6.3.2.3.1 Pen injectors are generally used when medications have to be administered more than once a week
                                         TABLE 70 COMMERCIALLY AVAILABLE KEY PEN INJECTORS
                                         TABLE 71 PEN INJECTORS MARKET, BY REGION, 2016–2019 (USD BILLION)
                                         TABLE 72 PEN INJECTORS MARKET, BY REGION, 2020–2025 (USD BILLION)
                    6.3.2.4 Wearable injectors
                               6.3.2.4.1 Increasing adoption of home infusion therapy and rising focus on cost-curtailment in healthcare are supporting market growth
                                         TABLE 73 WEARABLE INJECTORS MARKET, BY REGION, 2016–2019 (USD MILLION)
                                         TABLE 74 WEARABLE INJECTORS MARKET, BY REGION, 2020–2025 (USD MILLION)
           6.3.3 OTHER INJECTOR DEVICES
                 TABLE 75 OTHER INJECTOR DEVICES MARKET, BY REGION, 2016–2019 (USD BILLION)
                 TABLE 76 OTHER INJECTOR DEVICES MARKET, BY REGION, 2020–2025 (USD BILLION)
    6.4 TOPICAL DRUG DELIVERY
        TABLE 77 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016–2019 (USD BILLION)
        TABLE 78 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2020–2025 (USD BILLION)
        TABLE 79 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 80 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD BILLION)
           6.4.1 LIQUID FORMULATIONS
                 TABLE 81 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD BILLION)
                 TABLE 82 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
                 TABLE 83 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY REGION, 2016–2019 (USD BILLION)
                 TABLE 84 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY REGION, 2020–2025 (USD BILLION)
                    6.4.1.1 Solutions
                               6.4.1.1.1 Solutions accounted for a larger share of the topical drug delivery technology market for liquid formulations in 2018
                                         TABLE 85 TOPICAL SOLUTIONS MARKET, BY REGION, 2016–2019 (USD BILLION)
                                         TABLE 86 TOPICAL SOLUTIONS MARKET, BY REGION, 2020–2025 (USD BILLION)
                    6.4.1.2 Suspensions
                               6.4.1.2.1 Factors such as higher rate of bioavailability and the controlled onset of action to support the growth of the topical suspensions market in the coming years
                                         TABLE 87 TOPICAL SUSPENSIONS MARKET, BY REGION, 2016–2019 (USD BILLION)
                                         TABLE 88 TOPICAL SUSPENSIONS MARKET, BY REGION, 2020–2025 (USD BILLION)
           6.4.2 SEMI-SOLID FORMULATIONS
                 TABLE 89 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD BILLION)
                 TABLE 90 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
                 TABLE 91 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY REGION, 2016–2019 (USD BILLION)
                 TABLE 92 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY REGION, 2020–2025 (USD BILLION)
                    6.4.2.1 Creams
                               6.4.2.1.1 Creams are either water-in-oil or oil-in-water emulsions
                                         TABLE 93 TOPICAL CREAMS MARKET, BY REGION, 2016–2019 (USD BILLION)
                                         TABLE 94 TOPICAL CREAMS MARKET, BY REGION, 2020–2025 (USD BILLION)
                    6.4.2.2 Gels
                               6.4.2.2.1 Faster drug release and greater patient acceptability are the key factors driving the market for topical gels
                                         TABLE 95 TOPICAL GELS MARKET, BY REGION, 2016–2019 (USD MILLION)
                                         TABLE 96 TOPICAL GELS MARKET, BY REGION, 2020–2025 (USD MILLION)
                    6.4.2.3 Ointments
                               6.4.2.3.1 Ointments are widely used in analgesic indications
                                         TABLE 97 TOPICAL OINTMENTS MARKET, BY REGION, 2016–2019 (USD BILLION)
                                         TABLE 98 TOPICAL OINTMENTS MARKET, BY REGION, 2020–2025 (USD BILLION)
                    6.4.2.4 Pastes
                               6.4.2.4.1 Topical pastes are widely used for the treatment and prevention of skin irritation
                                         TABLE 99 TOPICAL PASTES MARKET, BY REGION, 2016–2019 (USD MILLION)
                                         TABLE 100 TOPICAL PASTES MARKET, BY REGION, 2020–2025 (USD MILLION)
                    6.4.2.5 Lotions
                               6.4.2.5.1 Easy administration of lotions to drive their demand among end users
                                         TABLE 101 TOPICAL LOTIONS MARKET, BY REGION, 2016–2019 (USD BILLION)
                                         TABLE 102 TOPICAL LOTIONS MARKET, BY REGION, 2020–2025 (USD BILLION)
           6.4.3 SOLID FORMULATIONS
                 TABLE 103 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD MILLION)
                 TABLE 104 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD MILLION)
                 TABLE 105 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY REGION, 2016–2019 (USD MILLION)
                 TABLE 106 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY REGION, 2020–2025 (USD MILLION)
                    6.4.3.1 Suppositories
                               6.4.3.1.1 Suppositories require a suitable base that ensures the compatibility and stability of the drug
                                         TABLE 107 TOPICAL SUPPOSITORIES MARKET, BY REGION, 2016–2019 (USD MILLION)
                                         TABLE 108 TOPICAL SUPPOSITORIES MARKET, BY REGION, 2020–2025 (USD MILLION)
                    6.4.3.2 Powders
                               6.4.3.2.1 Powders have a very fine particle size that covers a large surface area per unit weight
                                         TABLE 109 TOPICAL POWDERS MARKET, BY REGION, 2016–2019 (USD BILLION)
                                         TABLE 110 TOPICAL POWDERS MARKET, BY REGION, 2020–2025 (USD BILLION)
           6.4.4 TRANSDERMAL PRODUCTS
                 TABLE 111 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2016–2019 (USD BILLION)
                 TABLE 112 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD BILLION)
                 TABLE 113 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY REGION, 2016–2019 (USD BILLION)
                 TABLE 114 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY REGION, 2020–2025 (USD BILLION)
                    6.4.4.1 Transdermal patches
                               6.4.4.1.1 Transdermal patches prevent the premature metabolization of the drug through the liver
                                         TABLE 115 TRANSDERMAL PATCHES MARKET, BY REGION, 2016–2019 (USD MILLION)
                                         TABLE 116 TRANSDERMAL PATCHES MARKET, BY REGION, 2020–2025 (USD MILLION)
                    6.4.4.2 Transdermal gels
                               6.4.4.2.1 Transdermal gels help in the faster release of drugs on the target site
                                         TABLE 117 TRANSDERMAL GELS MARKET, BY REGION, 2016–2019 (USD MILLION)
                                         TABLE 118 TRANSDERMAL GELS MARKET, BY REGION, 2020–2025 (USD MILLION)
    6.5 OCULAR DRUG DELIVERY
        TABLE 119 OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016–2019 (USD BILLION)
        TABLE 120 OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2020–2025 (USD BILLION)
        TABLE 121 OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 122 OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD BILLION)
           6.5.1 LIQUID FORMULATIONS
                 TABLE 123 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD BILLION)
                 TABLE 124 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
                 TABLE 125 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY REGION, 2016–2019 (USD BILLION)
                 TABLE 126 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY REGION, 2020–2025 (USD BILLION)
                    6.5.1.1 Eye drops
                               6.5.1.1.1 Rising prevalence of cataracts and other eye diseases is driving market growth
                                         TABLE 127 COMMERCIALLY AVAILABLE EYE DROPS
                                         TABLE 128 EYE DROPS MARKET, BY REGION, 2016–2019 (USD BILLION)
                                         TABLE 129 EYE DROPS MARKET, BY REGION, 2020–2025 (USD BILLION)
                    6.5.1.2 Liquid sprays
                               6.5.1.2.1 Liquid sprays have helped in overcoming drawbacks associated with traditional eye drops
                                         TABLE 130 LIQUID SPRAYS MARKET, BY REGION, 2016–2019 (USD BILLION)
                                         TABLE 131 LIQUID SPRAYS MARKET, BY REGION, 2020–2025 (USD BILLION)
           6.5.2 SEMI-SOLID FORMULATIONS
                 TABLE 132 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD MILLION)
                 TABLE 133 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD MILLION)
                 TABLE 134 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY REGION, 2016–2019 (USD MILLION)
                 TABLE 135 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY REGION, 2020–2025 (USD MILLION)
                    6.5.2.1 Gels
                               6.5.2.1.1 High viscosity of drugs, prolonged drug release, and ease of drug administration are factors contributing to market growth
                                         TABLE 136 OCULAR GELS MARKET, BY REGION, 2016–2019 (USD MILLION)
                                         TABLE 137 OCULAR GELS MARKET, BY REGION, 2020–2025 (USD MILLION)
                    6.5.2.2 Eye ointments
                               6.5.2.2.1 Eye ointments are safe to use, and help in improving ocular contact time with the drug
                                         TABLE 138 EYE OINTMENTS MARKET, BY REGION, 2016–2019 (USD MILLION)
                                         TABLE 139 EYE OINTMENTS MARKET, BY REGION, 2020–2025 (USD MILLION)
           6.5.3 OCULAR DEVICES
                 TABLE 140 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2016–2019 (USD MILLION)
                 TABLE 141 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2020–2025 (USD MILLION)
                 TABLE 142 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY REGION, 2016–2019 (USD MILLION)
                 TABLE 143 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY REGION, 2020–2025 (USD MILLION)
                    6.5.3.1 Drug-coated contact lenses
                               6.5.3.1.1 Better eyesight offered by lenses & high compliance to drive the market for drug-coated contact lenses
                                         TABLE 144 DRUG-COATED CONTACT LENSES MARKET, BY REGION, 2016–2019 (USD MILLION)
                                         TABLE 145 DRUG-COATED CONTACT LENSES MARKET, BY REGION, 2020–2025 (USD MILLION)
                    6.5.3.2 Ocular inserts
                               6.5.3.2.1 Ocular inserts help in the sustained release of drugs in the eye
                                         TABLE 146 OCULAR INSERTS MARKET, BY REGION, 2016–2019 (USD MILLION)
                                         TABLE 147 OCULAR INSERTS MARKET, BY REGION, 2020–2025 (USD MILLION)
    6.6 PULMONARY DRUG DELIVERY
        TABLE 148 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016–2019 (USD BILLION)
        TABLE 149 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2020–2025 (USD BILLION)
        TABLE 150 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 151 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD BILLION)
           6.6.1 METERED-DOSE INHALERS
                    6.6.1.1 These inhalers overcome the problem of poor coordination between inhaler actuation and patient breath
                            TABLE 152 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR METERED-DOSE INHALERS, BY REGION, 2016–2019 (USD BILLION)
                            TABLE 153 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR METERED-DOSE INHALERS, BY REGION, 2020–2025 (USD BILLION)
           6.6.2 DRY POWDER INHALERS
                    6.6.2.1 DPI drug formulations are chemically more stable than their counterparts
                            TABLE 154 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR DRY POWDER INHALERS, BY REGION, 2016–2019 (USD BILLION)
                            TABLE 155 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR DRY POWDER INHALERS, BY REGION, 2020–2025 (USD BILLION)
           6.6.3 NEBULIZERS
                 TABLE 156 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2016–2019 (USD BILLION)
                 TABLE 157 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2020–2025 (USD BILLION)
                 TABLE 158 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY REGION, 2016–2019 (USD BILLION)
                 TABLE 159 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY REGION, 2020–2025 (USD BILLION)
                    6.6.3.1 Jet nebulizers
                               6.6.3.1.1 Jet nebulizers account for the largest share of the nebulizers market
                                         TABLE 160 JET NEBULIZERS MARKET, BY REGION, 2016–2019 (USD MILLION)
                                         TABLE 161 JET NEBULIZERS MARKET, BY REGION, 2020–2025 (USD MILLION)
                    6.6.3.2 Ultrasonic nebulizers
                               6.6.3.2.1 Ultrasonic nebulizers are easy to use and comfortable to handle
                                         TABLE 162 ULTRASONIC NEBULIZERS MARKET, BY REGION, 2016–2019 (USD MILLION)
                                         TABLE 163 ULTRASONIC NEBULIZERS MARKET, BY REGION, 2020–2025 (USD MILLION)
                    6.6.3.3 Soft mist nebulizers
                               6.6.3.3.1 Soft mist nebulizers are preferred for the treatment of severe COPD
                                         TABLE 164 SOFT MIST NEBULIZERS MARKET, BY REGION, 2016–2019 (USD MILLION)
                                         TABLE 165 SOFT MIST NEBULIZERS MARKET, BY REGION, 2020–2025 (USD MILLION)
    6.7 NASAL DRUG DELIVERY
        TABLE 166 NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016–2019 (USD BILLION)
        TABLE 167 NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2020–2025 (USD BILLION)
        TABLE 168 NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016–2019 (USD BILLION)
        TABLE 169 NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2020–2025 (USD BILLION)
           6.7.1 NASAL DROPS
                    6.7.1.1 Nasal drops are considered more efficient than nasal sprays
                            TABLE 170 NASAL DROPS MARKET, BY REGION, 2016–2019 (USD BILLION)
                            TABLE 171 NASAL DROPS MARKET, BY REGION, 2020–2025 (USD BILLION)
           6.7.2 NASAL SPRAYS
                    6.7.2.1 Nasal sprays help in relieving nasal congestion, runny nose, itchy nose, and sneezing
                            TABLE 172 NASAL SPRAYS MARKET, BY REGION, 2016–2019 (USD BILLION)
                            TABLE 173 NASAL SPRAYS MARKET, BY REGION, 2020–2025 (USD BILLION)
           6.7.3 NASAL POWDERS
                    6.7.3.1 Absence of preservatives & superior stability of formulations are some of the advantages associated with nasal powders
                            TABLE 174 NASAL POWDERS MARKET, BY REGION, 2016–2019 (USD MILLION)
                            TABLE 175 NASAL POWDERS MARKET, BY REGION, 2020–2025 (USD MILLION)
           6.7.4 NASAL GELS
                    6.7.4.1 Nasal gels provide long-lasting relief from dry nasal passages and also reduce irritation caused by using soothing excipients
                            TABLE 176 NASAL GELS MARKET, BY REGION, 2016–2019 (USD MILLION)
                            TABLE 177 NASAL GELS MARKET, BY REGION, 2020–2025 (USD MILLION)
    6.8 TRANSMUCOSAL DRUG DELIVERY
        TABLE 178 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016–2019 (USD BILLION)
        TABLE 179 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2020–2025 (USD BILLION)
        TABLE 180 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 181 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD BILLION)
           6.8.1 ORAL FORMULATIONS
                 TABLE 182 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2016–2019 (USD BILLION)
                 TABLE 183 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2020–2025 (USD BILLION)
                 TABLE 184 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY REGION, 2016–2019 (USD BILLION)
                 TABLE 185 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY REGION, 2020–2025 (USD BILLION)
                    6.8.1.1 Buccal drug delivery
                               6.8.1.1.1 Buccal drug delivery system is suitable for local and systematic therapies
                                         TABLE 186 BUCCAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016–2019 (USD BILLION)
                                         TABLE 187 BUCCAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2020–2025 (USD BILLION)
                    6.8.1.2 Sublingual drug delivery
                               6.8.1.2.1 The rate of drug absorption through the sublingual route is 3–10 times higher than the oral route
                                         TABLE 188 SUBLINGUAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016–2019 (USD BILLION)
                                         TABLE 189 SUBLINGUAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2020–2025 (USD BILLION)
           6.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES
                 TABLE 190 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2016–2019 (USD MILLION)
                 TABLE 191 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                 TABLE 192 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY REGION, 2016–2019 (USD MILLION)
                 TABLE 193 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY REGION, 2020–2025 (USD MILLION)
                    6.8.2.1 Rectal transmucosal drug delivery
                               6.8.2.1.1 The rectal route of drug delivery rapidly absorbs drugs that are aqueous in nature
                                         TABLE 194 RECTAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016–2019 (USD MILLION)
                                         TABLE 195 RECTAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2020–2025 (USD MILLION)
                    6.8.2.2 Vaginal transmucosal drug delivery
                               6.8.2.2.1 The permeability of the drug is high through the vaginal route of administration
                                         TABLE 196 VAGINAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016–2019 (USD MILLION)
                                         TABLE 197 VAGINAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2020–2025 (USD MILLION)
    6.9 IMPLANTABLE DRUG DELIVERY
        TABLE 198 IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016–2019 (USD BILLION)
        TABLE 199 IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2020–2025 (USD BILLION)
        TABLE 200 IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 201 IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD MILLION)
           6.9.1 ACTIVE IMPLANTABLE DRUG DELIVERY
                    6.9.1.1 Active implantable devices are used for diagnostic monitoring, body fluids transportation, and ionized radiation
                            TABLE 202 ACTIVE IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016–2019 (USD MILLION)
                            TABLE 203 ACTIVE IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2020–2025 (USD MILLION)
           6.9.2 PASSIVE IMPLANTABLE DRUG DELIVERY
                    6.9.2.1 Passive implants primarily include joint replacements, heart valves, aneurysm clips, coronary stents, and breast implants
                            TABLE 204 PASSIVE IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016–2019 (USD MILLION)
                            TABLE 205 PASSIVE IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2020–2025 (USD MILLION)

7 DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE (Page No. - 186)
    7.1 INTRODUCTION
        FIGURE 21 HOME CARE SETTINGS TO WITNESS THE HIGHEST GROWTH IN THE DRUG DELIVERY TECHNOLOGY MARKET FROM 2020 TO 2025
        TABLE 206 DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016–2019 (USD BILLION)
        TABLE 207 DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020–2025 (USD BILLION)
    7.2 HOSPITALS
           7.2.1 HOSPITALS WILL CONTINUE TO DOMINATE THE DRUG DELIVERY TECHNOLOGY MARKET DURING THE FORECAST PERIOD
                  TABLE 208 DRUG DELIVERY TECHNOLOGY MARKET FOR HOSPITALS, BY REGION, 2016–2019 (USD BILLION)
                  TABLE 209 DRUG DELIVERY TECHNOLOGY MARKET FOR HOSPITALS, BY REGION, 2020–2025 (USD BILLION)
    7.3 AMBULATORY SURGERY CENTERS/CLINICS
           7.3.1 INCREASING PREFERENCE FOR ASCS HAS RESULTED IN A SIGNIFICANT RISE IN DEMAND FOR DRUG DELIVERY TECHNOLOGIES
                  TABLE 210 DRUG DELIVERY TECHNOLOGY MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY REGION, 2016–2019 (USD BILLION)
                  TABLE 211 DRUG DELIVERY TECHNOLOGY MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY REGION, 2020–2025 (USD BILLION)
    7.4 HOME CARE SETTINGS
           7.4.1 HOME CARE SETTINGS TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
                  TABLE 212 DRUG DELIVERY TECHNOLOGY MARKET FOR HOME CARE SETTINGS, BY REGION, 2016–2019 (USD BILLION)
                  TABLE 213 DRUG DELIVERY TECHNOLOGY MARKET FOR HOME CARE SETTINGS, BY REGION, 2020–2025 (USD BILLION)
    7.5 DIAGNOSTIC CENTERS
           7.5.1 RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH
                  TABLE 214 DRUG DELIVERY TECHNOLOGY MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2016–2019 (USD BILLION)
                  TABLE 215 DRUG DELIVERY TECHNOLOGY MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2020–2025 (USD BILLION)
    7.6 OTHER FACILITIES OF USE
        TABLE 216 DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FACILITIES OF USE, BY REGION, 2016–2019 (USD BILLION)
        TABLE 217 DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FACILITIES OF USE, BY REGION, 2020–2025 (USD BILLION)

8 DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION (Page No. - 193)
    8.1 INTRODUCTION
    8.2 COVID-19 IMPACT, BY APPLICATION
        FIGURE 22 INFECTIOUS DISEASES SEGMENT WILL DOMINATE THE DRUG DELIVERY TECHNOLOGY MARKET DURING THE FORECAST PERIOD
        TABLE 218 DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2016–2019 (USD BILLION)
        TABLE 219 DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2020–2025 (USD BILLION)
    8.3 INFECTIOUS DISEASES
           8.3.1 HIGH BURDEN OF INFECTIOUS DISEASES ACROSS THE GLOBE TO DRIVE MARKET GROWTH
                  TABLE 220 DRUG DELIVERY TECHNOLOGY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2016–2019 (USD BILLION)
                  TABLE 221 DRUG DELIVERY TECHNOLOGY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2025 (USD BILLION)
    8.4 CANCER
           8.4.1 CANCER FORMS A KEY THERAPEUTIC APPLICATION SEGMENT FOR DRUG DELIVERY TECHNOLOGIES
                  TABLE 222 DRUG DELIVERY TECHNOLOGY MARKET FOR CANCER, BY REGION, 2016–2019 (USD BILLION)
                  TABLE 223 DRUG DELIVERY TECHNOLOGY MARKET FOR CANCER, BY REGION, 2020–2025 (USD BILLION)
    8.5 CARDIOVASCULAR DISEASES
           8.5.1 INCREASING PREVALENCE OF CVD IS DRIVING THE GROWTH OF THE DRUG DELIVERY TECHNOLOGY MARKET
                  TABLE 224 DRUG DELIVERY TECHNOLOGY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2016–2019 (USD BILLION)
                  TABLE 225 DRUG DELIVERY TECHNOLOGY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2025 (USD BILLION)
    8.6 DIABETES
           8.6.1 EMERGENCE OF NEW TECHNOLOGIES IS SUPPORTING MARKET GROWTH
                  TABLE 226 DRUG DELIVERY TECHNOLOGY MARKET FOR DIABETES, BY REGION, 2016–2019 (USD BILLION)
                  TABLE 227 DRUG DELIVERY TECHNOLOGY MARKET FOR DIABETES, BY REGION, 2020–2025 (USD BILLION)
    8.7 RESPIRATORY DISEASES
           8.7.1 HIGH PREVALENCE OF ASTHMA & COPD TO DRIVE THE ADOPTION OF DRUG DELIVERY TECHNOLOGIES
                  TABLE 228 DRUG DELIVERY TECHNOLOGY MARKET FOR RESPIRATORY DISEASES, BY REGION, 2016–2019 (USD BILLION)
                  TABLE 229 DRUG DELIVERY TECHNOLOGY MARKET FOR RESPIRATORY DISEASES, BY REGION, 2020–2025 (USD BILLION)
    8.8 CENTRAL NERVOUS SYSTEM DISORDERS
           8.8.1 ORAL AND INJECTABLE DRUG DELIVERY SYSTEMS ARE WIDELY USED IN THE TREATMENT OF CNS DISORDERS
                  TABLE 230 DRUG DELIVERY TECHNOLOGY MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2016–2019 (USD BILLION)
                  TABLE 231 DRUG DELIVERY TECHNOLOGY MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2020–2025 (USD BILLION)
    8.9 AUTOIMMUNE DISEASES
           8.9.1 AUTOIMMUNE DISEASES SEGMENT TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD
                  TABLE 232 DRUG DELIVERY TECHNOLOGY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2016–2019 (USD BILLION)
                  TABLE 233 DRUG DELIVERY TECHNOLOGY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2020–2025 (USD BILLION)
    8.10 OTHER APPLICATIONS
           8.10.1 OPHTHALMIC DISORDERS
           8.10.2 ENDOCRINE DISORDERS
                  TABLE 234 DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER APPLICATIONS, BY REGION, 2016–2019 (USD BILLION)
                  TABLE 235 DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2025 (USD BILLION)

9 DRUG DELIVERY TECHNOLOGY MARKET, BY REGION (Page No. - 205)
    9.1 INTRODUCTION
        TABLE 236 DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016–2019 (USD BILLION)
        TABLE 237 DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2020–2025 (USD BILLION)
    9.2 NORTH AMERICA
        FIGURE 23 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT
        TABLE 238 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016–2019 (USD BILLION)
        TABLE 239 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2020–2025 (USD BILLION)
        TABLE 240 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2019 (USD BILLION)
        TABLE 241 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD BILLION)
        TABLE 242 NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 243 NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD BILLION)
        TABLE 244 NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2016–2019 (USD BILLION)
        TABLE 245 NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 246 NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2016–2019 (USD BILLION)
        TABLE 247 NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 248 NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2016–2019 (USD BILLION)
        TABLE 249 NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 250 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 251 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD BILLION)
        TABLE 252 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2016–2019 (USD BILLION)
        TABLE 253 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2020–2025 (USD BILLION)
        TABLE 254 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2016–2019 (USD BILLION)
        TABLE 255 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2020–2025 (USD BILLION)
        TABLE 256 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2016–2019 (USD BILLION)
        TABLE 257 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2020–2025 (USD BILLION)
        TABLE 258 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 259 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2020–2025 (USD BILLION)
        TABLE 260 NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 261 NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD BILLION)
        TABLE 262 NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD BILLION)
        TABLE 263 NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 264 NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD MILLION)
        TABLE 265 NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD MILLION)
        TABLE 266 NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 267 NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 268 NORTH AMERICA: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016–2019 (USD MILLION)
        TABLE 269 NORTH AMERICA: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2020–2025 (USD MILLION)
        TABLE 270 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 271 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD BILLION)
        TABLE 272 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD BILLION)
        TABLE 273 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 274 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD MILLION)
        TABLE 275 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD MILLION)
        TABLE 276 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD MILLION)
        TABLE 277 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD MILLION)
        TABLE 278 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 279 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 280 NORTH AMERICA: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 281 NORTH AMERICA: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 282 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 283 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 284 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 285 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2020–2025 (USD BILLION)
        TABLE 286 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 287 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 288 NORTH AMERICA: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 289 NORTH AMERICA: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD BILLION)
        TABLE 290 NORTH AMERICA: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 291 NORTH AMERICA: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 292 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2016–2019 (USD BILLION)
        TABLE 293 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2020–2025 (USD BILLION)
        TABLE 294 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016–2019 (USD BILLION)
        TABLE 295 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020–2025 (USD BILLION)
           9.2.1 US
                    9.2.1.1 Rising prevalence of chronic diseases and the strong presence of key market players are driving market growth in the US
                            TABLE 296 US: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2019 (USD BILLION)
                            TABLE 297 US: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD BILLION)
                            TABLE 298 US: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016–2019 (USD BILLION)
                            TABLE 299 US: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020–2025 (USD BILLION)
           9.2.2 CANADA
                    9.2.2.1 Government support for research and the rising prevalence of chronic diseases are driving the market in Canada
                            TABLE 300 CANADA: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2019 (USD BILLION)
                            TABLE 301 CANADA: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD BILLION)
                            TABLE 302 CANADA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016–2019 (USD BILLION)
                            TABLE 303 CANADA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020–2025 (USD BILLION)
    9.3 EUROPE
        FIGURE 24 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT
        TABLE 304 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016–2019 (USD BILLION)
        TABLE 305 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2020–2025 (USD BILLION)
        TABLE 306 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2019 (USD BILLION)
        TABLE 307 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD BILLION)
        TABLE 308 EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 309 EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD BILLION)
        TABLE 310 EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2016–2019 (USD BILLION)
        TABLE 311 EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 312 EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2016–2019 (USD BILLION)
        TABLE 313 EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 314 EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2016–2019 (USD BILLION)
        TABLE 315 EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 316 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 317 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD BILLION)
        TABLE 318 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2016–2019 (USD BILLION)
        TABLE 319 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2020–2025 (USD BILLION)
        TABLE 320 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2016–2019 (USD BILLION)
        TABLE 321 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2020–2025 (USD BILLION)
        TABLE 322 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2016–2019 (USD BILLION)
        TABLE 323 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2020–2025 (USD BILLION)
        TABLE 324 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 325 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2020–2025 (USD BILLION)
        TABLE 326 EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 327 EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD BILLION)
        TABLE 328 EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD BILLION)
        TABLE 329 EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2025–2025 (USD BILLION)
        TABLE 330 EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD BILLION)
        TABLE 331 EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 332 EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 333 EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 334 EUROPE: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016–2019 (USD MILLION)
        TABLE 335 EUROPE: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2020–2025 (USD MILLION)
        TABLE 336 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 337 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD BILLION)
        TABLE 338 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD BILLION)
        TABLE 339 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 340 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD BILLION)
        TABLE 341 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 342 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD MILLION)
        TABLE 343 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD MILLION)
        TABLE 344 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 345 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 346 EUROPE: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 347 EUROPE: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 348 EUROPE: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 349 EUROPE: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD BILLION)
        TABLE 350 EUROPE: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 351 EUROPE: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2020–2025 (USD BILLION)
        TABLE 352 EUROPE: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 353 EUROPE: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 354 EUROPE: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 355 EUROPE: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD BILLION)
        TABLE 356 EUROPE: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 357 EUROPE: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 358 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2016–2019 (USD BILLION)
        TABLE 359 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2020–2025 (USD BILLION)
        TABLE 360 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016–2019 (USD BILLION)
        TABLE 361 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020–2025 (USD BILLION)
           9.3.1 GERMANY
                    9.3.1.1 Growing focus of pharmaceutical companies on the development of various drug delivery products is expected to drive market growth in Germany
                            TABLE 362 GERMANY: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2019 (USD BILLION)
                            TABLE 363 GERMANY: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD BILLION)
                            TABLE 364 GERMANY: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016–2019 (USD BILLION)
                            TABLE 365 GERMANY: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020–2025 (USD BILLION)
           9.3.2 FRANCE
                    9.3.2.1 High insurance coverage coupled with the increasing prevalence of chronic diseases to drive market growth in France
                            TABLE 366 FRANCE: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2019 (USD BILLION)
                            TABLE 367 FRANCE: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD BILLION)
                            TABLE 368 FRANCE: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016–2019 (USD BILLION)
                            TABLE 369 FRANCE: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020–2025 (USD BILLION)
           9.3.3 UK
                    9.3.3.1 Increasing incidence and prevalence of chronic and infectious diseases to drive the demand for drug delivery technologies in the UK
                            TABLE 370 UK: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2019 (USD BILLION)
                            TABLE 371 UK: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD BILLION)
                            TABLE 372 UK: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016–2019 (USD BILLION)
                            TABLE 373 UK: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020–2025 (USD BILLION)
           9.3.4 REST OF EUROPE
                 TABLE 374 ROE: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2019 (USD BILLION)
                 TABLE 375 ROE: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD BILLION)
                 TABLE 376 ROE: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016–2019 (USD BILLION)
                 TABLE 377 ROE: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020–2025 (USD BILLION)
    9.4 ASIA PACIFIC
        FIGURE 25 ASIA PACIFIC: DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT
        TABLE 378 APAC: DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2019 (USD BILLION)
        TABLE 379 APAC: DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2020–2025 (USD BILLION)
        TABLE 380 APAC: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2019 (USD BILLION)
        TABLE 381 APAC: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD BILLION)
        TABLE 382 APAC: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016-2019 (USD BILLION)
        TABLE 383 APAC: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 384 APAC: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
        TABLE 385 APAC: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 386 APAC: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
        TABLE 387 APAC: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 388 APAC: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
        TABLE 389 APAC: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 390 APAC: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD BILLION)
        TABLE 391 APAC: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD BILLION)
        TABLE 392 APAC: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2016–2019 (USD BILLION)
        TABLE 393 APAC: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2020–2025 (USD BILLION)
        TABLE 394 APAC: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2016–2019 (USD BILLION)
        TABLE 395 APAC: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2020–2025 (USD BILLION)
        TABLE 396 APAC: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2016–2019 (USD BILLION)
        TABLE 397 APAC: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2020–2025 (USD BILLION)
        TABLE 398 APAC: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 399 APAC: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2020–2025 (USD BILLION)
        TABLE 400 APAC: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 401 APAC: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD BILLION)
        TABLE 402 APAC: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD BILLION)
        TABLE 403 APAC: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 404 APAC: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD MILLION)
        TABLE 405 APAC: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD MILLION)
        TABLE 406 APAC: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 407 APAC: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 408 APAC: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016–2019 (USD MILLION)
        TABLE 409 APAC: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2020–2025 (USD MILLION)
        TABLE 410 APAC: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 411 APAC: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD BILLION)
        TABLE 412 APAC: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD BILLION)
        TABLE 413 APAC: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 414 APAC: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD BILLION)
        TABLE 415 APAC: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 416 APAC: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD MILLION)
        TABLE 417 APAC: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD MILLION)
        TABLE 418 APAC: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 419 APAC: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 420 APAC: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 421 APAC: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 422 APAC: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 423 APAC: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 424 APAC: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 425 APAC: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2020–2025 (USD BILLION)
        TABLE 426 APAC: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 427 APAC: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 428 APAC: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD BILLION)
        TABLE 429 APAC: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD BILLION)
        TABLE 430 APAC: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 431 APAC: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 432 APAC: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2016–2019 (USD BILLION)
        TABLE 433 APAC: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2020–2025 (USD BILLION)
        TABLE 434 APAC: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016–2019 (USD BILLION)
        TABLE 435 APAC: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020–2025 (USD BILLION)
           9.4.1 JAPAN
                    9.4.1.1 Favorable government initiatives and increasing geriatric population will drive market growth in Japan
                            TABLE 436 JAPAN: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2019 (USD BILLION)
                            TABLE 437 JAPAN: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD BILLION)
                            TABLE 438 JAPAN: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016–2019 (USD BILLION)
                            TABLE 439 JAPAN: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020–2025 (USD BILLION)
           9.4.2 CHINA
                    9.4.2.1 China had the largest diabetic population in the world in 2017
                            TABLE 440 CHINA: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2019 (USD BILLION)
                            TABLE 441 CHINA: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD BILLION)
                            TABLE 442 CHINA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016–2019 (USD BILLION)
                            TABLE 443 CHINA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020–2025 (USD BILLION)
           9.4.3 INDIA
                    9.4.3.1 Favorable initiatives and high disease incidence will drive market growth in India
                            TABLE 444 INDIA: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2019 (USD BILLION)
                            TABLE 445 INDIA: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD BILLION)
                            TABLE 446 INDIA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016–2019 (USD BILLION)
                            TABLE 447 INDIA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020–2025 (USD BILLION)
           9.4.4 REST OF ASIA PACIFIC
                 TABLE 448 ROAPAC: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2019 (USD MILLION)
                 TABLE 449 ROAPAC: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION)
                 TABLE 450 ROA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016–2019 (USD BILLION)
                 TABLE 451 ROA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020–2025 (USD BILLION)
    9.5 REST OF THE WORLD
        FIGURE 26 ROW: DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT
        TABLE 452 ROW: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2019 (USD BILLION)
        TABLE 453 ROW: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD BILLION)
        TABLE 454 ROW: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016-2019 (USD BILLION)
        TABLE 455 ROW: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 456 ROW: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
        TABLE 457 ROW: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 458 ROW: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2016-2019 (USD BILLION)
        TABLE 459 ROW: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 460 ROW: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2016-2019 (USD MILLION)
        TABLE 461 ROW: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2020–2025 (USD MILLION)
        TABLE 462 ROW: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2019 (USD MILLION)
        TABLE 463 ROW: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 464 ROW: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2016–2019 (USD BILLION)
        TABLE 465 ROW: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2020–2025 (USD BILLION)
        TABLE 466 ROW: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2016–2019 (USD BILLION)
        TABLE 467 ROW: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2020–2025 (USD BILLION)
        TABLE 468 ROW: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2016–2019 (USD BILLION)
        TABLE 469 ROW: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2020–2025 (USD BILLION)
        TABLE 470 ROW: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 471 ROW: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 472 ROW: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 473 ROW: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 474 ROW: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD BILLION)
        TABLE 475 ROW: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD BILLION)
        TABLE 476 ROW: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD MILLION)
        TABLE 477 ROW: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD MILLION)
        TABLE 478 ROW: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 479 ROW: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 480 ROW: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016–2019 (USD MILLION)
        TABLE 481 ROW: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2020–2025 (USD MILLION)
        TABLE 482 ROW: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 483 ROW: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 484 ROW: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD MILLION)
        TABLE 485 ROW: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD MILLION)
        TABLE 486 ROW: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD MILLION)
        TABLE 487 ROW: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD MILLION)
        TABLE 488 ROW: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2019 (USD MILLION)
        TABLE 489 ROW: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2020–2025 (USD MILLION)
        TABLE 490 ROW: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 491 ROW: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 492 ROW: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 493 ROW: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 494 ROW: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 495 ROW: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 496 ROW: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 497 ROW: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 498 ROW: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 499 ROW: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 500 ROW: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 501 ROW: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 502 ROW: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2016–2019 (USD MILLION)
        TABLE 503 ROW: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 504 ROW: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2016–2019 (USD BILLION)
        TABLE 505 ROW: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2020–2025 (USD BILLION)
        TABLE 506 ROW: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016–2019 (USD BILLION)
        TABLE 507 ROW: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2020–2025 (USD BILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 312)
     10.1 OVERVIEW
          FIGURE 27 KEY DEVELOPMENTS IN THE DRUG DELIVERY TECHNOLOGY MARKET FROM 2017 TO 2020
     10.2 MARKET PLAYER RANKING, 2020
          TABLE 508 DRUG DELIVERY TECHNOLOGY MARKET PLAYER RANKING, 2020
     10.3 COMPETITIVE SCENARIO
          TABLE 509 PRODUCT LAUNCHES AND APPROVALS, 2018–2020
          TABLE 510 COLLABORATIONS, AGREEMENTS, AND JOINT VENTURES, 2016–2020
          TABLE 511 ACQUISITIONS, 2018–2020
          TABLE 512 EXPANSIONS, 2018–2020
     10.4 COMPETITIVE LEADERSHIP MAPPING (2019)
             10.4.1 VENDOR INCLUSION CRITERIA
             10.4.2 VISIONARY LEADERS
             10.4.3 INNOVATORS
             10.4.4 DYNAMIC DIFFERENTIATORS
             10.4.5 EMERGING COMPANIES
                    FIGURE 28 MNM DIVE-VENDOR COMPARISON MATRIX: DRUG DELIVERY TECHNOLOGY MARKET
     10.5 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2019)
             10.5.1 PROGRESSIVE COMPANIES
             10.5.2 STARTING BLOCKS
             10.5.3 RESPONSIVE COMPANIES
             10.5.4 DYNAMIC COMPANIES
                    FIGURE 29 MNM DIVE-VENDOR COMPARISON MATRIX FOR START-UPS: DRUG DELIVERY TECHNOLOGY MARKET

11 COMPANY PROFILES (Page No. - 321)
(Business Overview, Products Offered, Recent Developments, MnM View)*
     11.1 JOHNSON & JOHNSON SERVICES, INC.
          FIGURE 30 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2019)
     11.2 NOVARTIS AG
          FIGURE 31 NOVARTIS AG: COMPANY SNAPSHOT (2019)
     11.3 F. HOFFMANN-LA ROCHE LTD.
          FIGURE 32 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2019)
     11.4 PFIZER, INC.
          FIGURE 33 PFIZER, INC.: COMPANY SNAPSHOT (2019)
     11.5 BAYER AG
          FIGURE 34 BAYER AG: COMPANY SNAPSHOT (2019)
     11.6 ANTARES PHARMA, INC.
          FIGURE 35 ANTARES PHARMA, INC.: COMPANY SNAPSHOT (2019)
     11.7 BECTON, DICKINSON AND COMPANY
          FIGURE 36 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2019)
     11.8 GLAXOSMITHKLINE PLC
          FIGURE 37 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2019)
     11.9 3M
          FIGURE 38 3M: COMPANY SNAPSHOT (2019)
     11.10 MERCK & CO., INC.
           FIGURE 39 MERCK & CO., INC.: COMPANY SNAPSHOT (2019)
     11.11 SANOFI
           FIGURE 40 SANOFI: COMPANY SNAPSHOT (2019)
     11.12 ABBVIE
           FIGURE 41 ABBVIE: COMPANY SNAPSHOT (2019)
     11.13 AMGEN
           FIGURE 42 AMGEN: COMPANY SNAPSHOT (2019)
     11.14 BOEHRINGER INGELHEIM
           FIGURE 43 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2019)
     11.15 ASTRAZENECA
           FIGURE 44 ASTRAZENECA: COMPANY SNAPSHOT (2019)
     11.16 ELI LILLY AND COMPANY
           FIGURE 45 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2019)
     11.17 GILEAD SCIENCES
           FIGURE 46 GILEAD SCIENCES: COMPANY SNAPSHOT (2019)
     11.18 GENMAB A/S
           FIGURE 47 GENMAB: COMPANY SNAPSHOT (2019)
     11.19 TEVA PHARMACEUTICALS
     11.20 BRISTOL-MYERS SQUIBB
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

12 ADJACENT/RELATED MARKETS (Page No. - 440)
     12.1 INTRODUCTION
     12.2 MARKET DEFINITION & SCOPE
     12.3 LIMITATIONS
     12.4 MARKET OVERVIEW
          FIGURE 48 HOME CARE SETTINGS TO DOMINATE THE AUTOINJECTORS MARKET DURING THE FORECAST PERIOD
     12.5 AUTOINJECTORS MARKET, BY TYPE
             12.5.1 ACCESSORIES & CONSUMABLES
                    TABLE 513 DISPOSABLE AUTOINJECTORS MARKET, BY COUNTRY, 2016–2023 (USD BILLION)
             12.5.2 REUSABLE AUTOINJECTORS
                    TABLE 514 REUSABLE AUTOINJECTORS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
     12.6 AUTOINJECTORS PUMP MARKET, BY END USER
          FIGURE 49 AUTOINJECTORS MARKET, BY END USER, 2018 VS. 2023 (USD BILLION)
          TABLE 515 AUTOINJECTORS MARKET, BY END USER, 2016–2023 (USD BILLION)
             12.6.1 HOME CARE SETTING
                    TABLE 516 AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2016–2023 (USD BILLION)
             12.6.2 HOSPITALS & CLINICS
                    TABLE 517 AUTOINJECTORS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2016–2023 (USD MILLION)
     12.7 AUTOINJECTORS MARKET, BY REGION
             12.7.1 NORTH AMERICA
                    TABLE 518 NORTH AMERICA: AUTOINJECTORS MARKET, BY END USER, 2016–2023 (USD BILLION)
             12.7.2 EUROPE
                    TABLE 519 EUROPE: AUTOINJECTORS MARKET, BY END USER, 2016–2023 (USD BILLION)
             12.7.3 ASIA PACIFIC
                    TABLE 520 ASIA PACIFIC: AUTOINJECTORS MARKET, BY END USER, 2016–2023 (USD BILLION)
             12.7.4 LATIN AMERICA
                    TABLE 521 ROW: AUTOINJECTORS MARKET, BY END USER, 2016–2023 (USD BILLION)

13 APPENDIX (Page No. - 450)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 AVAILABLE CUSTOMIZATIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS

This study involved four major activities to estimate the current size of the pharmaceutical drug delivery market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was mainly used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the pharmaceutical drug delivery market. Secondary sources such as the Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), Health Canada, American Journal of Drug Delivery and Therapeutics, Center for Drug Delivery and Nanomedicine, Parenteral Drug Association (PDA), International Journal of Drug Delivery, Annual Reports, Press Releases, SEC Filings, and Investor Presentations were used. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Pharmaceutical Drug Delivery Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total market size for pharmaceutical drug delivery technology market was arrived at after data triangulation from two different approaches, as mentioned below:

Approach to calculate the revenue of different players in the pharmaceutical drug delivery technology market

  • Revenues for individual companies operating in the pharmaceutical drug delivery technology market were gathered from public sources and databases
  • Share of each product type of leading players was gathered from secondary sources to the extent available. In certain cases, the share of pharmaceutical drug delivery technology business has been ascertained after a detailed analysis of various parameters, including the product portfolio, market positioning, and geographic reach & strength, among others
  • Individual shares or revenue estimates were validated through expert interviews
  • The impact of COVID-19 was assessed using the quarterly reports of the companies and applied to the global market for impact assessment

Approach to derive the market size and estimate market growth

  • As a part of the primary research process, an individual respondent’s insights on the market size and market growth were taken during the interview (regional and global, as applicable)
  • All the responses were collated, and a weighted average was taken to derive a probabilistic estimate of the market size and growth rate

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global pharmaceutical drug delivery market on the basis of route of administration, application, facility of use, and region
  • To provide detailed information about the factors influencing market growth (drivers, restraints, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the total market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of market segments in North America, Europe, Asia Pacific, and the Rest of the World
  • To profile key players and comprehensively analyze their product portfolios, market rankings, and core competencies
  • To track and analyze competitive developments, such as acquisitions, collaboration, product approvals, expansions, and agreements in the global pharmaceutical drug delivery market

    Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top companies

Geographic Analysis

  • Further breakdown of the RoAPAC market into South Korea, New Zealand, Australia, Singapore, and other countries
  • Further breakdown of the RoE market into Russia, the Netherlands, Switzerland, and other countries

Company Information

  • Detailed analysis and profiling of additional market players, up to five
COVID-19

Get in-depth analysis of the COVID-19 impact on the Pharmaceutical Drug Delivery Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Pharmaceutical Drug Delivery Market

Request For Special Pricing
Report Code
MD 3871
Published ON
Jul, 2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Pharmaceutical Drug Delivery Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2020 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home